Browsing Tag
Rusfertide
5 posts
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet
Takeda has secured FDA approval for MIMRYLO in adults with polycythemia vera, triggering $275 million of payments to Protagonist Therapeutics and opening a launch Takeda believes could ultimately generate $1 billion to $2 billion in peak global sales.
Takeda is paying Insilico $600m to find drugs before humans take over
Takeda signs a $600 million Insilico AI drug deal. Read how Pharma.AI could reshape pipeline economics, R&D productivity and investor sentiment.
Does Priority Review signal a commercial breakthrough for Protagonist Therapeutics, Inc.?
Takeda and Protagonist secure FDA Priority Review for rusfertide in PV. Explore the strategic, financial, and competitive implications now.
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
How Protagonist Therapeutics is building a multi‑indication macrocyclic peptide portfolio with icotrokinra and beyond
Protagonist Therapeutics is building a multi-indication oral biologics platform with icotrokinra and rusfertide. Learn how its macrocyclic peptides are redefining therapy.